ThinkstockDividend payments by S&P 500 companies reached an all-time high last year, totaling some $330.8 billion, according to FactSet. As of this March, 418 of the 500 companies in the index paid…
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it…
UPS reported first-quarter 2014 results before markets opened Thursday, and no surprise, winter weather was its theme of the day. And no surprise either that shares slipped after the opening bell.
Eli Lilly reported disappointing first-quarter 2014 results before markets opened Thursday, due in part to the impact of U.S. patent expirations for Cymbalta and Evista. Shares were up in premarket trading.
Trey Thoelcke These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, April 3, 2014. They include Apple, Intel, Chevron, Exxon, Qualcomm and Citigroup.
The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically behave in the mid-term years after a solid first quarter. Here are…
In a new research report, Cowen analysts posted a list of some of the top new datapoints cited at the Cowen 2014 Healthcare Conference by large cap pharmaceutical companies concerning upcoming events…
Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to outperform for the balance of 2014. Here are some of the top…
Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added to the Piper Jaffray Model Portfolio.
Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer immunotherapy portfolio.
With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good chance for investors to get timely updates on the top stocks and…
Ariad Pharmaceuticals could be joining the ranks of the next big biotech acquisitions. The company fits the bill of many biotech acquirers because its market cap is just over $1 billion and…
Jon C. Ogg ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020, but Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has acquired rights to launch its…
Jon OggNow that we are mostly through earnings season and now that stocks have challenged all-time highs recently, investors and traders alike have to start thinking about how to position themselves for…
courtesy Deere & Co.UBS has a list of stocks that investors may want to consider selling. They could even be a list of short sale candidates. The UBS team is bashing Apache…
